Morphic Holding Inc's Comment on Sales, Marketing and Customers
The company develops oral small-molecule integrin therapeutics for patients with serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, cancer, and inflammatory bowel disease (IBD). Its lead product candidate, MORF-057, targets IBD. The company is also advancing projects focused on the IL23 and TL1A pathways related to inflammation and immunology. Its strategy involves establishing orally available integrin modulators as new treatments and expanding its pipeline to address diseases caused by integrin dysregulation with high unmet medical needs. Customers and markets mentioned in filings include ArQule, Inc., Biogen Inc., Cubist Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Pharmacia Corporation, Takeda Pharmaceutical Company Limited, and Theravance Biopharma, Inc.
Morphic Holding Inc’s Comment on Sales, Marketing and Customers
The company develops oral small-molecule integrin therapeutics for patients with serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, cancer, and inflammatory bowel disease (IBD). Its lead product candidate, MORF-057, targets IBD. The company is also advancing projects focused on the IL23 and TL1A pathways related to inflammation and immunology. Its strategy involves establishing orally available integrin modulators as new treatments and expanding its pipeline to address diseases caused by integrin dysregulation with high unmet medical needs. Customers and markets mentioned in filings include ArQule, Inc., Biogen Inc., Cubist Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Pharmacia Corporation, Takeda Pharmaceutical Company Limited, and Theravance Biopharma, Inc.
Sources:
Morphic Holding inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Morphic Holding inc’s corporate clients.
For your research, we’ve provided 9 tables on Morphic Holding inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
